Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Bellicum Pharmaceuticals
Thumbnail
February 22, 2022

Biontech follows Immatics and goes after Prame

Thumbnail
November 09, 2021

SITC 2021 – Immatics’ T-cell receptor success was no fluke

Article image
Vantage logo
November 02, 2020

Kiadis makes nothing into €325m

Sanofi goes all in on Kiadis's natural killer cell projects, gained through an all-stock deal in 2019.

Article image
Vantage logo
October 30, 2020

After six years Bellicum admits it’s not ready for prime time

Yet another makeover raises fresh questions over Bellicum’s technology and sees its valuation haemorrhage some more.

Article image
Vantage logo
November 14, 2019

Lead discontinuation is a start, but Kiadis’s problems continue

Article image
Vantage logo
October 18, 2019

Kiadis falls, and Bellicum could be next

EU rejection of Kiadis's stem cell transplant adjunct means that two of three players in this space have been knocked back.

Article image
Vantage logo
September 24, 2019

Does amount matter when it comes to a biotech IPO?

Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.

Article image
Vantage logo
August 28, 2019

Immatics and Adaptimmune show that T-cell receptor deals aren't dead

Article image
Vantage logo
June 28, 2019

Twilight of the stem cell transplant adjuncts?

The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.

Article image
Vantage logo
June 05, 2019

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.

Article image
Vantage logo
April 23, 2019

A Nasdaq float is scrapped, but for Poseida that’s great news

The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 12, 2022

Q2 Roundup Infographic

August 10, 2022

Q2 Roundup eBook

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.